Nephrology
Sibeprenlimab Demonstrates Kidney Function Preservation in IgA Nephropathy: Insights from the Final Phase 3 VISIONARY Trial
The phase 3 VISIONARY trial establishes sibeprenlimab as a promising therapy in IgA nephropathy, significantly stabilizing eGFR decline and reducing kidney-function deterioration over 24 months with a favorable safety profile.
